Introduction President Donald Trump signed an executive order on April 18, 2026, directing the Food and Drug Administration to accelerate its review of certain psychedelic compounds, including ibogaine, for the treatment of serious mental illness. The order marks the first time the federal government has formally moved to expedite ibogaine FDA approval, a development that...
